EDRN Prostate MRI Biomarker Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2019
The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.
Epistemonikos ID: 1183f87fe7e1ff97937fc19417b553eb6b2fbca7
First added on: May 21, 2024